CTOs on the Move

Promentis Pharmaceuticals

www.promentispharma.com

 
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Promentis Pharmaceuticals raised $26M on 03/30/2017

Similar Companies

Diamedica

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Eli Lilly

Lilly makes medicines that help people live longer, healthier, more active lives. We were founded by Eli Lilly in 1876, and are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Lilly is consistently ranked as one of the best companies in the world to work for, and generations of Lilly employees have sustained a culture that values excellence, integrity, and respect for people. We make medicines that help people live longer, healthier, more active lives.

Bio-Pharm Inc

Bio-Pharm Inc is a Levittown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Cardioxyl Pharmaceuticals

Cardioxyl Pharmaceuticals is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.